Trial intelligence / Profile preview

Imaging of Solid Tumors Using DLL3 SPECT

NCT07052760Phase 1Withdrawn

Start: Apr 2026
Primary completion: May 2028
Modality: Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies

Overview

Phase 1, open-label trial of 111In-ABD147 in solid tumor, castration-resistant prostate cancer (CRPC) and Neuroendocrine Neoplasm (NEN) (3 cohorts). Primary endpoints: Standardized Uptake Values at 2 days and Tumor-to-background ratio at 2 days. Planned start Apr 2026; status: withdrawn.

Drugs

111In-ABD147

Conditions

solid tumorcastration-resistant prostate cancer (CRPC)Neuroendocrine Neoplasm (NEN)

Beyond the preview

Go deeper on NCT07052760.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07052760.